Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 14/20 | 0.53 |
| ▸ | SELE | P16581 | 14/20 | 0.53 |
| ▸ | VCAM1 | P19320 | 6/20 | 0.53 |
| ▸ | CDK8 | P49336 | 7/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3708981 | 0.79 | ICAM1 (0.56) | ICAM1SELEVCAM1CDK8PIM1 | |
| SCHEMBL30744177 | 0.76 | ICAM1 (0.57) | ICAM1SELEVCAM1CDK8PIM1 | |
| SCHEMBL20319767 | 0.76 | ALDH1A1 (0.32) | ICAM1SELEVCAM1CDK8PIM1 | |
| SCHEMBL5334846 | 0.76 | ICAM1 (0.34) | ICAM1SELEVCAM1CDK8PIM1 | |
| SCHEMBL23093512 | 0.76 | ICAM1 (0.57) | ICAM1SELEVCAM1CDK8PIM1 | |
| SCHEMBL23109949 | 0.76 | ICAM1 (0.49) | ICAM1SELEVCAM1CDK8PIM1 | |
| SCHEMBL4885757 | 0.76 | SELE (0.51) | ICAM1SELEVCAM1CDK8PIM1 | |
| SCHEMBL5376106 | 0.72 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL24845323 | 0.72 | ICAM1 (0.45) | ICAM1SELEVCAM1CDK8PIM1 | |
| SCHEMBL23522277 | 0.72 | ICAM1 (0.53) | ICAM1SELEVCAM1CDK8PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019018359-A1 | THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS | SAINT LOUIS UNIVERSITY (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-3356330-A1 | BIARYL KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2007056215-A9 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA INC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007056215-A2 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | ICAM1 1970/4885SELE 1316/4885VCAM1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.